The divested assets include Benvenue’s Kiva VCF treatment system, the Kiva Pilot and Blazer vertebral augmentation system devices, Santa Clara, Calif.-based Benvenue Medical said.
Benvenue said that with the sale, the company will focus on its Luna 3D interbody fusion system, and that it will continue its surgeon-focused spine device development and US operations.
“IZI Medical’s acquisition of the Kiva and associated VCF product franchise allows us to singularly focus on our minimally invasive spinal implant and procedure product line. Our best-in-class Luna 3D Expandable Interbody System is an ideal minimally invasive expandable spinal implant and platform technology, enabling Nitinol, PEEK and Titanium materials to be combined in a procedural solution for degenerative disc disease that can be treated in either the hospital or the ASC setting,” Benvenue CEO Robert Weigle said in a press release.
IZI Medical said that the acquisition will complement its existing vertebroplasty and bone biopsy lines, including its Duro-Ject, Osteo-Site, Osteo-Force, Vertefix and Murphy brands of needles, injectors and cements.
“Benvenue Medical’s Kiva vertebral body implant technology coupled with our vertebroplasty product line will allow us to offer patients a wide range of treatments for various spinal fractures. We will continue to build on their legacy with our dedicated product development team and growing sales network,” IZI Medical CEO Greg Groenke said in a prepared statement.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.